top of page
We are developing this for the acute cardioversion of atrial fibrillation (AF) to sinus rhythm through an intravenous infusion. Phase 2 results from this serves a proof-of-concept for the general mechanism of SK inhibition to treat AF.
We are developing this for maintenance of sinus rhythm in patients with atrial fibrillation. It is being developed for chronic oral (tablet) treatment.
bottom of page